Abbott Accelerates US Health Tech Growth with Major Investment
Chicago, Wednesday, 20 August 2025.
Abbott’s strategic investment in US manufacturing aims to create hundreds of jobs and boost health technology innovation across three states. This positions Abbott as a leader in advanced healthcare solutions in America.
Expanding Manufacturing and R&D in the USA
In an ambitious push to bolster its domestic operations, Abbott has committed to substantial investments in U.S. manufacturing and research and development (R&D) across three states. This initiative is a part of Abbott’s broader strategy to enhance its health tech capabilities, which is slated to create hundreds of jobs and significantly boost local economies [1]. In April 2025, Abbott announced a $500 million investment specifically aimed at expanding its transfusion diagnostics business. This move alone is expected to generate 300 new jobs [1].
Targeting Cardiovascular and Diagnostic Markets
Among Abbott’s investments is a planned cardiovascular device manufacturing facility in Georgia, projected for completion by 2028 [1]. In addition, this initiative includes entering the molecular nucleic acid blood and plasma testing market, a sector estimated to represent a $1 billion opportunity for the company [1]. Such strategic expansions underscore Abbott’s focus on leveraging technological advancements to maintain its competitive edge in the healthcare industry.
Harnessing Advanced Technology for Health
Abbott’s thrust into advanced health technologies is not just limited to physical infrastructure. The company has been actively exploring innovative diagnostic solutions, such as the Alinity s System—a high-throughput, fully-automated immunoassay analyzer designed for donor screening [1]. This system exemplifies Abbott’s commitment to integrating cutting-edge technology with practical healthcare applications to meet unmet global needs.
The Broader Industry Context
Abbott’s expansion aligns with a broader industry trend towards enhancing domestic manufacturing capabilities and integrating advanced technology into healthcare solutions. For instance, Philips has similarly announced a $150 million investment to expand AI health technology offerings in the United States, focusing on expanding facilities in Pennsylvania and Minnesota [2][3]. Such investments reflect the increasing importance of technological innovation in health tech, an area where Abbott aims to continue leading.